Generic Pricing Pressure and Erosion: The generic pharmaceutical market faces continuous pressure from new entrants, buyer consolidation, and government initiatives, leading to declining prices and eroded profit margins for Amneal's core generic business.

Regulatory Compliance and Enforcement Risks: Amneal operates in a highly regulated environment, and any failure to comply with FDA, DEA, or international regulations, including manufacturing standards (cGMP) or product safety, could result in significant fines, product recalls, facility closures, or delays in product approvals.

Product Pipeline Development and Approval Challenges: The success of Amneal's specialty and biosimilar segments, as well as the longevity of its generic business, depends on its ability to successfully develop, receive regulatory approval for, and launch new products, which is subject to clinical trial failures, unexpected side effects, and prolonged approval processes.